Market Growth: The super generics market is forecasted to grow from USD 205 billion in 2023 to USD 413 billion by 2033, at a ...

This growth was, to a large degree, driven by the generics market that showed an impressive growth rate of 14 per cent by value over the last decade (CAGR 2001-2009) reaching a size of almost 90 ...

The differences between the generics industry and other pharma companies wouldn’t exist without patents – legal titles that exclude others from producing or using an invention or innovation ...

India’s decentralised drug regulation system grants significant authority to State Drug Regulatory Authorities, leading to ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

U.S. bans generic sales of obesity drug Zepbound due to supply resolution U.S. to halt generic production of Zepbound obesity ...

China’s aggressive drive to replace brand-name foreign drugs with dirt-cheap homegrown generics has already taken a toll on ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

The pharma company said the settlement—which will be paid before Dec. 31 subject to court approval—was included in its ...

After offloading a big chunk of their Japanese generics joint venture in 2020, Teva and Takeda have decided to divest the business in its entirety so they can each focus on their innovative medicines.